论文部分内容阅读
目的:探讨伏立康唑治疗恶性血液病患者合并侵袭性真菌感染(IF I)的结果。方法:选择山西医科大学第二医院血液科2006年2月-2007年5月收治的恶性血液病合并IF I患者20例,采用常规剂量的伏立康唑序贯治疗。结果:20例IF I患者总治愈率和有效率分别为61.1%和83.3%。结论:恶性血液病合并侵袭性真菌感染者应用伏立康唑治疗有效,副作用小,安全性高。
Objective: To investigate the results of voriconazole in patients with hematologic malignancies complicated with invasive fungal infection (IF I). Methods: Twenty patients with hematologic malignancies complicated with IF I who were admitted to Department of Hematology, the Second Hospital of Shanxi Medical University from February 2006 to May 2007 were selected and treated with conventional doses of voriconazole. Results: The total cure rate and effective rate of 20 IFI patients were 61.1% and 83.3% respectively. Conclusion: Voriconazole is effective in patients with hematologic malignancies complicated with invasive fungal infections with less side effects and high safety.